

Joseph L Chin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2955608/publications.pdf>

Version: 2024-02-01

116
papers

4,872
citations

230014

27
h-index

107981

68
g-index

125
all docs

125
docs citations

125
times ranked

4348
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized phase II trial of neoadjuvant abiraterone plus or minus cabazitaxel in high-risk prostate cancer: ACDC-RP.. Journal of Clinical Oncology, 2022, 40, 224-224.	0.8	3
2	Cognition and depression effects of androgen receptor axis-targeted drugs in men with prostate cancer: A systematic review. Journal of Geriatric Oncology, 2021, 12, 687-695.	0.5	17
3	Prostatic dystrophic calcification following salvage cryotherapy for prostate cancer – an under-reported entity?. Scandinavian Journal of Urology, 2021, 55, 33-35.	0.6	1
4	Magnetic resonance imaging-guided transurethral ultrasound ablation in patients with localised prostate cancer: 3-year outcomes of a prospective Phase I study. BJU International, 2021, 127, 544-552.	1.3	13
5	Long-term outcomes of two ablation techniques for treatment of radio-recurrent prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 186-192.	2.0	2
6	Relief of Lower Urinary Tract Symptoms After MRI-Guided Transurethral Ultrasound Ablation for Localized Prostate Cancer: Subgroup Analyses in Patients with Concurrent Cancer and Benign Prostatic Hyperplasia. Journal of Endourology, 2021, 35, 497-505.	1.1	12
7	Comparison of Multiparametric Magnetic Resonance Imaging-Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer. JAMA Oncology, 2021, 7, 534.	3.4	99
8	Radiation oncologist consultations prior to prostatectomy in Ontario, Canada: Disparities and opportunities.. Journal of Clinical Oncology, 2021, 39, e17052-e17052.	0.8	0
9	Prostate specific membrane antigen positron emission tomography for lesion-directed high-dose-rate brachytherapy dose escalation. Physics and Imaging in Radiation Oncology, 2021, 19, 102-107.	1.2	0
10	Characterizing Surgical and Radiotherapy Outcomes in Non-metastatic High-Risk Prostate Cancer: A Systematic Review and Meta-Analysis. Cureus, 2021, 13, e17400.	0.2	1
11	Propensity score matching versus coarsened exact matching in observational comparative effectiveness research. Journal of Comparative Effectiveness Research, 2021, 10, 939-951.	0.6	10
12	Long-Term Outcomes of Whole Gland Salvage Cryotherapy for Locally Recurrent Prostate Cancer following Radiation Therapy: A Combined Analysis of Two Centers. Journal of Urology, 2021, 206, 646-654.	0.2	2
13	Primary Mediastinal Germ Cell Tumors – The University of Western Ontario Experience. Current Oncology, 2021, 28, 78-85.	0.9	6
14	Short-duration dynamic [18F]DCFPyL PET and CT perfusion imaging to localize dominant intraprostatic lesions in prostate cancer: validation against digital histopathology and comparison to [18F]DCFPyL PET/MR at 120 minutes. EJNMMI Research, 2021, 11, 107.	1.1	2
15	Dosimetric Evaluation of PSMA PET-Delineated Dominant Intraprostatic Lesion Simultaneous Infield Boosts. Advances in Radiation Oncology, 2020, 5, 212-220.	0.6	16
16	The Singularity is Near(ish): Emerging Applications of Artificial Intelligence in Prostate Cancer Management. European Urology, 2020, 77, 293-295.	0.9	4
17	Histologic validation of auto-contoured dominant intraprostatic lesions on [18F] DCFPyL PSMA-PET imaging. Radiotherapy and Oncology, 2020, 152, 34-41.	0.3	8
18	Does adding local salvage ablation therapy provide survival advantage for patients with locally recurrent prostate cancer following radiotherapy?. Canadian Urological Association Journal, 2020, 15, 123-129.	0.3	4

#	ARTICLE	IF	CITATIONS
19	Histologic tissue components provide major cues for machine learning-based prostate cancer detection and grading on prostatectomy specimens. <i>Scientific Reports</i> , 2020, 10, 9911.	1.6	22
20	The History of Cryosurgery in Canada: A Tale of Two Cities. <i>Canadian Urological Association Journal</i> , 2020, 14, 299-304.	0.3	0
21	Re: Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. <i>European Urology</i> , 2020, 78, 765-766.	0.9	0
22	A Novel Salvage Option for Local Failure in Prostate Cancer, Reirradiation Using External Beam or Stereotactic Radiation Therapy: Systematic Review and Meta-Analysis. <i>Advances in Radiation Oncology</i> , 2020, 5, 965-977.	0.6	29
23	Salvage open radical prostatectomy for recurrent prostate cancer following MRI-guided transurethral ultrasound ablation (TULSA) of the prostate: feasibility and efficacy. <i>Scandinavian Journal of Urology</i> , 2020, 54, 215-219.	0.6	10
24	The prevalence of cardiovascular disease and its risk factors among prostate cancer patients treated with and without androgen deprivation.. <i>Journal of Clinical Oncology</i> , 2020, 38, 364-364.	0.8	6
25	Comparative efficacy of local versus systemic salvage therapies for recurrent prostate cancer after primary radiotherapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 221-221.	0.8	0
26	Cryosurgery Versus Primary Androgen Deprivation Therapy for Locally Recurrent Prostate Cancer After Primary Radiotherapy: A Propensity-Matched Survival Analysis. <i>Cureus</i> , 2020, 12, e7983.	0.2	3
27	Multiparametric magnetic resonance imaging of multifocal prostate cancer to reveal intra-prostatic genomic heterogeneity and novel radio-genomic correlates: Results of the Smarter Prostate Interventions and Therapeutics (SPIRIT) study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 20-20.	0.8	0
28	A three-gene DNA methylation biomarker accurately classifies early stage prostate cancer. <i>Prostate</i> , 2019, 79, 1705-1714.	1.2	24
29	Are There Extended Benefits with Extended Lymph Node Dissection During Radical Prostatectomy?. <i>European Urology</i> , 2018, 74, 138-139.	0.9	2
30	Re: Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. <i>European Urology</i> , 2018, 73, 808.	0.9	0
31	¹⁹ F-perfluorocarbon-labeled human peripheral blood mononuclear cells can be detected in vivo using clinical MRI parameters in a therapeutic cell setting. <i>Scientific Reports</i> , 2018, 8, 590.	1.6	42
32	[¹⁸ F]-DCFPyL Positron Emission Tomography/Magnetic Resonance Imaging for Localization of Dominant Intraprostatic Foci: First Experience. <i>European Urology Focus</i> , 2018, 4, 702-706.	1.6	21
33	Robotic-assisted Radical Prostatectomy for High-risk Cancer: Time for "Sexta-fecta". <i>European Urology</i> , 2018, 73, 224-225.	0.9	1
34	Editorial Comment on: Focal Treatment for Unilateral Prostate Cancer Using High-Intensity Focal Ultrasound: A Comprehensive Study of Pooled Data by Albisinni et al. <i>Journal of Endourology</i> , 2018, 32, 805-805.	1.1	0
35	Editorial Comment on Tay et al.. <i>Journal of Endourology</i> , 2017, 31, 572-572.	1.1	0
36	Pathological, Oncologic and Functional Outcomes of a Prospective Registry of Salvage High Intensity Focused Ultrasound Ablation for Radiorecurrent Prostate Cancer. <i>Journal of Urology</i> , 2017, 197, 97-102.	0.2	27

#	ARTICLE	IF	CITATIONS
37	Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update. <i>Journal of Clinical Oncology</i> , 2017, 35, 1737-1743.	0.8	128
38	Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update Summary. <i>Journal of Oncology Practice</i> , 2017, 13, 392-394.	2.5	10
39	Abiraterone +/- cabazitaxel in defining complete response in prostatectomy (ACDC-RP) trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS5095-TPS5095.	0.8	0
40	Assessment of histopathological features of needle biopsy in recurrent prostate cancer following salvage high-intensity focused ultrasound. <i>Canadian Urological Association Journal</i> , 2016, 10, 416.	0.3	4
41	Toward Prostate Cancer Contouring Guidelines on Magnetic Resonance Imaging: Dominant Lesion Gross and Clinical Target Volume Coverage Via Accurate Histology Fusion. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 188-196.	0.4	26
42	Recurrent retroperitoneal inflammatory myofibroblastic tumor: A case report. <i>Oncology Letters</i> , 2016, 12, 1535-1538.	0.8	6
43	Long-Term Oncologic Outcomes of Salvage Cryoablation for Radio-Recurrent Prostate Cancer. <i>Journal of Urology</i> , 2016, 196, 1105-1111.	0.2	17
44	Magnetic Resonance Imagingâ€“Guided Transurethral Ultrasound Ablation of Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase 1 Clinical Trial. <i>European Urology</i> , 2016, 70, 447-455.	0.9	73
45	Development and evaluation of the TrueNTH-Prostate Cancer Canada electronic Library for Improved (urinary and bowel) Function post Treatment (TrueNTH-PCC-eLIFT).. <i>Journal of Clinical Oncology</i> , 2016, 34, 161-161.	0.8	0
46	Re: Salvage Focal Prostate Cryoablation for Locally Recurrent Prostate Cancer After Radiotherapy: Initial Results from the Cryo On-line Data Registry. <i>European Urology</i> , 2015, 67, 813.	0.9	0
47	Targeting the VEGF pathway in metastatic bladder cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 913-927.	1.9	35
48	A Brief Survey of Active Surveillance. <i>European Urology</i> , 2015, 68, 812-813.	0.9	0
49	Comparative morbidity of ablative energy-based salvage treatments for radio-recurrent prostate cancer. <i>Canadian Urological Association Journal</i> , 2015, 9, 325.	0.3	16
50	CUA-CUOG CRPC Guidelines: A useful compendium. <i>Canadian Urological Association Journal</i> , 2015, 9, 224.	0.3	0
51	Effect of dutasteride in men receiving intermittent androgen ablation therapy: The AVIAS trial. <i>Canadian Urological Association Journal</i> , 2014, 8, 789.	0.3	9
52	Growth kinetics of small renal masses: A prospective analysis from the Renal Cell Carcinoma Consortium of Canada. <i>Canadian Urological Association Journal</i> , 2014, 8, 24.	0.3	44
53	A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer. <i>Investigational New Drugs</i> , 2014, 32, 746-752.	1.2	26
54	Reply. <i>Urology</i> , 2014, 84, 1162.	0.5	0

#	ARTICLE	IF	CITATIONS
55	Salvage High-intensity Focused Ultrasound for Patients With Recurrent Prostate Cancer After Brachytherapy. <i>Urology</i> , 2014, 84, 1157-1162.	0.5	27
56	Dovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1553-1562.	1.9	15
57	Optimizing the Management of Pathologic, Possible, and Putative N1 Prostate Cancer. <i>European Urology</i> , 2014, 65, 563-564.	0.9	0
58	Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: Results from the Canadian Upper Tract Collaboration1Co-first authors.. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 839-845.	0.8	44
59	Following Radical Prostatectomy, To Beam or Not To Beam?. <i>European Urology</i> , 2013, 64, 565-566.	0.9	0
60	Low-dose rate brachytherapy for patients with low- or intermediate-risk prostate cancer: a systematic review. <i>Canadian Urological Association Journal</i> , 2013, 7, 463.	0.3	20
61	Salvage versus adjuvant radiotherapy after radical prostatectomy: argument for adjuvant radiotherapy. <i>Canadian Urological Association Journal</i> , 2013, 3, 241.	0.3	4
62	Urologists and radiation oncologists: working together for patient care. <i>Canadian Urological Association Journal</i> , 2013, 2, 204.	0.3	0
63	Residentsâ€™ training and evaluation: a personal reflection. <i>Canadian Urological Association Journal</i> , 2013, 4, 155.	0.3	0
64	Shared responsibility for treatment-related morbidity for prostate cancer. <i>Canadian Urological Association Journal</i> , 2013, 4, 112.	0.3	0
65	Clarifying the role of salvage radiotherapy. <i>Canadian Urological Association Journal</i> , 2013, 2, 508.	0.3	0
66	Low-dose rate brachytherapy for patients with low- or intermediate-risk prostate cancer: A systematic review. <i>Canadian Urological Association Journal</i> , 2013, 7, E783-7.	0.3	3
67	Apaziquone as an intravesical therapeutic agent for urothelial non-muscle-invasive bladder cancer. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 251-260.	1.9	13
68	Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy. <i>New England Journal of Medicine</i> , 2012, 367, 895-903.	13.9	428
69	High-Intensity Focused Ultrasound and Cryotherapy as Salvage Treatment in Local Radio-Recurrent Prostate Cancer. <i>Urologia Internationalis</i> , 2012, 89, 373-379.	0.6	12
70	Extended Followup Oncologic Outcome of Randomized Trial Between Cryoablation and External Beam Therapy for Locally Advanced Prostate Cancer (T2c-T3b). <i>Journal of Urology</i> , 2012, 188, 1170-1175.	0.2	40
71	Wholeâ€gland salvage highâ€intensity focused ultrasound therapy for localized prostate cancer recurrence after external beam radiation therapy. <i>Cancer</i> , 2012, 118, 3071-3078.	2.0	48
72	Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T?. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 99-108.	1.4	7

#	ARTICLE	IF	CITATIONS
73	Co-registration Framework for Histology-registration-based Validation of Fused Multimodality Prostate Cancer Imaging. , 2011, , .		0
74	Disease-Free Survival Following Salvage Cryotherapy for Biopsy-Proven Radio-Recurrent Prostate Cancer. European Urology, 2011, 60, 405-410.	0.9	103
75	Radical cystectomy for the treatment of T1 bladder cancer: the Canadian Bladder Cancer Network experience. Canadian Urological Association Journal, 2011, 5, 83-87.	0.3	16
76	Guideline for optimization of surgical and pathological quality performance for radical prostatectomy in prostate cancer management:evidentiary base. Canadian Urological Association Journal, 2010, 4, 13-25.	0.3	34
77	Molecular biomarkers in prostate cancer. Expert Opinion on Medical Diagnostics, 2009, 3, 345-353.	1.6	2
78	Postâ€“radical prostatectomy management options for the positive surgical margin: Argument for adjuvant radiotherapy. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 87-88.	0.8	8
79	Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial. Journal of Urology, 2009, 181, 956-962.	0.2	1,137
80	Multicenter Phase II Study of Combined Neoadjuvant Docetaxel and Hormone Therapy Before Radical Prostatectomy for Patients With High Risk Localized Prostate Cancer. Journal of Urology, 2008, 180, 565-570.	0.2	112
81	Review of Primary and Salvage Cryoablation for Prostate Cancer. Cancer Control, 2007, 14, 231-237.	0.7	29
82	Salvage Cryoablation of the Prostate: Followup and Analysis of Predictive Factors for Outcome. Journal of Urology, 2007, 178, 1253-1257.	0.2	107
83	Initial experience with robotic-assisted laparoscopic radical prostatectomy in the Canadian health care system. Canadian Urological Association Journal, 2007, 1, 97-101.	0.3	25
84	Adjuvant Radiotherapy for Pathologically Advanced Prostate Cancer. JAMA - Journal of the American Medical Association, 2006, 296, 2329.	3.8	833
85	1128: Salvage Cryoablation Outcomes - Analysis of Predictive Factors in a Large Cohort of Patients. Journal of Urology, 2006, 175, 363-363.	0.2	1
86	1130: Results of a Controlled Randomized Trial of Primary Cryoablation Versus External Beam Radiotherapy for Locally Advanced Prostate Cancer. Journal of Urology, 2006, 175, 363-364.	0.2	3
87	Current Status of Salvage Cryoablation for Prostate Cancer following Radiation Failure. Technology in Cancer Research and Treatment, 2005, 4, 211-216.	0.8	16
88	Increased intratumoral expression of prostate secretory protein of 94 amino acids predicts for worse disease recurrence and progression after radical prostatectomy in patients with prostate cancer. Urology, 2005, 65, 719-723.	0.5	24
89	CURRENT STATUS OF LOCAL SALVAGE THERAPIES FOLLOWING RADIATION FAILURE FOR PROSTATE CANCER. Journal of Urology, 2005, 173, 373-379.	0.2	129
90	Phased-array Magnetic Resonance Imaging of the Prostate with Correlation to Radical Prostatectomy Specimens: Local Experience. Asian Journal of Surgery, 2004, 27, 225-226.	0.2	3

#	ARTICLE	IF	CITATIONS
91	Serial Histopathology Results of Salvage Cryoablation for Prostate Cancer after Radiation Failure. Journal of Urology, 2003, 170, 1199-1202.	0.2	59
92	Clinical impact of adjunctive donor microvascular reconstruction on renal transplantation. Canadian Journal of Urology, 2003, 10, 1803-8.	0.0	6
93	New technologies for ablation of small renal tumors: current status. Canadian Journal of Urology, 2002, 9, 1576-82.	0.0	11
94	RESULTS OF SALVAGE CRYOABLATION OF THE PROSTATE AFTER RADIATION: IDENTIFYING PREDICTORS OF TREATMENT FAILURE AND COMPLICATIONS. Journal of Urology, 2001, 165, 1937-1942.	0.2	149
95	RESULTS OF SALVAGE CRYOABLATION OF THE PROSTATE AFTER RADIATION:. Journal of Urology, 2001, 165, 1937-1942.	0.2	57
96	Serum bound forms of PSP94 (prostate secretory protein of 94 amino acids) in prostate cancer patients. , 2000, 76, 71-83.		17
97	Differential expression of PSP94 in rat prostate lobes as demonstrated by an antibody against recombinant GST-PSP94. , 1999, 74, 406-417.		7
98	In situ hybridization study of PSP94 (prostatic secretory protein of 94 amino acids) expression in human prostates. , 1999, 41, 99-109.		36
99	UPPER TRACT UROKINASE INSTILLATION FOR NEPHROSTOMY TUBE PATENCY. Journal of Urology, 1999, 161, 538-540.	0.2	8
100	Three dimensional transrectal ultrasound imaging of the prostate: initial experience with an emerging technology. Canadian Journal of Urology, 1999, 6, 720-726.	0.0	11
101	THREE-DIMENSIONAL TRANSRECTAL ULTRASOUND GUIDED CRYOABLATION FOR LOCALIZED PROSTATE CANCER IN NONSURGICAL CANDIDATES: A FEASIBILITY STUDY AND REPORT OF EARLY RESULTS. Journal of Urology, 1998, 159, 910-914.	0.2	83
102	Analysis of epitope structure of PSP94 (prostate secretory protein of 94 amino acids): (I) immuno-dominant and immuno-recessive area. Journal of Cellular Biochemistry, 1997, 65, 172-185.	1.2	12
103	Analysis of epitope structure of PSP94 (prostate secretory protein of 94 amino acids): (II) epitope mapping by monoclonal antibodies. , 1997, 65, 186-197.		5
104	Recombinant PSP94 (prostate secretory protein of 94 amino acids) demonstrates similar linear epitope structure as natural PSP94 protein. Journal of Cellular Biochemistry, 1996, 63, 61-73.	1.2	13
105	Recombinant PSP94 (prostate secretory protein of 94 amino acids) demonstrates similar linear epitope structure as natural PSP94 protein. , 1996, 63, 61.		1
106	Fatal Air Embolism During Radical Retropubic Prostatectomy. Journal of Urology, 1994, 151, 433-434.	0.2	8
107	Metallothionein in testicular germ cell tumors and drug resistance: Clinical correlation. Cancer, 1993, 72, 3029-3035.	2.0	66
108	Intrarenal Bacillus Calmette-Guerin Therapy for Upper Urinary Tract Carcinoma in Situ. Journal of Urology, 1993, 149, 457-459.	0.2	92

#	ARTICLE	IF	CITATIONS
109	Loin Pain-Hematuria Syndrome: Role for Renal Autotransplantation. Journal of Urology, 1992, 147, 987-989.	0.2	29
110	Retrieval of Proximally Migrated Ureteral Stents. Journal of Urology, 1992, 148, 1205-1206.	0.2	39
111	Vena Caval Extension of Right Renal Vein for Cadaveric Renal Transplants. Journal of Urology, 1988, 139, 552-553.	0.2	16
112	Current Status of Chemotherapy Sensitivity Testing for Urological Malignancies. Journal of Urology, 1986, 136, 555-560.	0.2	11
113	Flow cytometric analysis of DNA content in human bladder tumors and irrigation fluids. Cancer, 1985, 56, 1677-1681.	2.0	59
114	Priapism and Anesthesia: New Considerations. Journal of Urology, 1983, 130, 371-371.	0.2	7
115	Melanoma Metastatic to the Bladder and Bowel: An Unusual Case. Journal of Urology, 1982, 127, 541-542.	0.2	5
116	Rodent PSP94 Gene Expression Is More Specific to the Dorsolateral Prostate and Less Sensitive to Androgen Ablation than Probasin. , 0, .		8